| Document |
Document Title |
|
WO/2020/264307A1 |
A probe for positron emission tomography (PET) is disclosed. The probe is selected from the group consisting of yersiniabactin (Ybt) labeled with Copper-64; staphylopine (StP) labeled with Copper-64; yersiniabactin (Ybt) labeled with Zir...
|
|
WO/2020/253824A1 |
The present invention belongs to the technical field of radiopharmaceutical chemistry, and provided are 18F-labeled fluoropicolinylglycine as well as a preparation method therefor and an application thereof. The 18F-labeled fluoropicolin...
|
|
WO/2020/257409A1 |
A composition comprising including a homogeneous tin- 117m colloid comprising tin- 117m, and an ascorbic acid is provided, the composition naturally has a white coloration. The composition is visually distinct from a conventional homogen...
|
|
WO/2020/254548A1 |
The invention comprises radiolabeled MOEM type oligonucleotide of the formula (I), (I) wherein n, X1, X2, the linker (1), the linker (2), Q* and the receptor targeting moiety are as defined (I) the description. The radiolabeled oligonucl...
|
|
WO/2020/252598A1 |
A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R0 is O or S. Each of R1a, R1b and R1c may be –CO2H, –SO2H, –SO3H, –PO2H, or –PO3H2,...
|
|
WO/2020/256545A1 |
Disclosed herein are compounds comprising trans-cyclooctene moieties, combinations, and kits that can be used to more quickly remove radionuclides from a subject, preferably a human being. Said compounds, combinations and kits can also b...
|
|
WO/2020/257690A1 |
A unique pipeline is employed for biomarker discovery that entailed domain antibody phage display, next generation sequencing analysis, and nanotechnology strategies to generate antibody mimetics are disclosed. Also disclosed are the tem...
|
|
WO/2020/257720A1 |
The present invention provides method of treating diseases, disorders and conditions in a human subject comprising administering to the subject a population of exosomes or a composition comprising a population of exosomes, wherein said p...
|
|
WO/2020/254934A1 |
The method for the preparation of lipid nanoparticles, comprises: the phase of mixing in a single container a mixture comprising an aqueous solution with a solid lipid matrix and with at least one biocompatible non-ionic surfactant; the ...
|
|
WO/2020/249818A1 |
The present invention relates to a composition comprising microparticles comprising a non-radioactive and a radioactive isotope, and an injection vehicle, for use in the intratumoral treatment of cancer, by combined antitumoral effect of...
|
|
WO/2020/249745A1 |
The present invention relates to cationic micelles, and in particular the compounds capable of forming such cationic micelles for use in cell tracking.
|
|
WO/2020/249980A1 |
There is described compounds, in particular compounds comprising a cMet binding cyclic peptide for human or animal administration and methods of use thereof. In particular, there is described compounds suitable for the preparation of an ...
|
|
WO/2020/247385A1 |
Described herein are methods and compositions for treating an inflammatory disease or infectious disease in a subject in need thereof by administering to the subject a poxvirus and a stem cell, wherein the disease is not a cancer. The di...
|
|
WO/2020/239046A1 |
Disclosed are a quinoxaline derivative and a preparation method therefor and the use thereof. Specifically provided are a compound as shown in formula I, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, or a solvate t...
|
|
WO/2020/239687A1 |
Novel 18F-labelled tetrazines are provided which are highly reactive to be effective in vivo, suitable for pretargeted positron emission tomography (PET) and accessible in radiochemical yields (RCYs) which allow access to 18F-labeled tet...
|
|
WO/2020/237399A1 |
A glass material that includes: from about 0.55 to about 0.85 mole fraction of SiO2; from about 0.01 to about 0.23 mole fraction of Na2O, K2O, or a combination of Na2O and K2O; from about 0.05 to about 0.28 mole fraction of: Y2O3, BaO, o...
|
|
WO/2020/242147A1 |
The present invention relates to a nanocarrier having a micellar structure, and a use thereof, and more specifically, to: a nanosome having a monolayer structure for delivering macromolecules; a drug carrier thereof; a contrast agent the...
|
|
WO/2020/238795A1 |
Disclosed are an rk polypeptide radiopharmaceutical targeting HER2, and a preparation method therefor. The rk polypeptide radiopharmaceutical comprises an rk polypeptide dimer and a radionuclide, wherein the radionuclide marks the rk pol...
|
|
WO/2020/243616A1 |
Provided herein are several monoclonal antibodies that activate the adhesion activity of human and mouse E-cadherin, including the amino acid sequences for the CDRs that define the binding domains of each monoclonal antibody. Also descri...
|
|
WO/2020/237290A1 |
The present invention relates to formulations of radiolabeled compounds that are of use in radiotherapy and diagnostic imaging related to prostate specific membrane antigen (PSMA).
|
|
WO/2020/238800A1 |
Provided are a structurally modified RGD polypeptide, a complex formed by the polypeptide and a radionuclide, and a pharmaceutical composition containing the complex, wherein the pharmaceutical composition is used for diagnosing or treat...
|
|
WO/2020/237195A1 |
A chemical synthesis platform based on a particularly simple chip is described herein, where reactions take place atop a hydrophobic substrate patterned with a circular hydrophilic liquid trap. The overall supporting hardware (heater, ro...
|
|
WO/2020/228558A1 |
Provided is a preparation method for a radioactive particle: preparing a first solution and a second solution, said first solution containing at least one type of positive ion and said second solution containing at least one type of nega...
|
|
WO/2020/228559A1 |
Provided is a radioactive particle, comprising a porous silicon dioxide particle and at least one type of radionuclide precipitate accommodated in the pores of the porous silicon dioxide particle. Said porous silicon dioxide particle is ...
|
|
WO/2020/229974A1 |
Macrocyclic chelators (I) for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordi...
|
|
WO/2020/225447A1 |
The present application discloses para-aminohippuric acid (PAhI) or a pharmaceutically acceptable salt or carboxylic acid derivate thereof for use in a method for the reduction of nephrotoxic side effects of radiolabeled and non-radiolab...
|
|
WO/2020/222161A1 |
This disclosure relates generally to compositions and methods for treating cancer. The compositions comprise bacterially derived intact minicells or intact killed bacterial cells.
|
|
WO/2020/222041A1 |
This invention provides a novel method that is simple, efficient, and allows for a reliable production of fluorine- 18 (18F) radiofluorinated compounds and radiopharmaceuticals. The method comprises an "in-loop" process, where an 18F sou...
|
|
WO/2020/221705A1 |
The present invention relates to a novel process for preparing a compound of formula (III) and rhenium chelated MAG3 oligonucleotides.
|
|
WO/2020/223057A1 |
The invention relates generally to peptide biomarkers with specific ionization characteristics to directly quantify one or more target HPPD proteins in biological samples, including crop plant samples, by liquid chromatography coupled ta...
|
|
WO/2020/220023A1 |
The present disclosure relates to compounds according to Formula I. These compounds display very good binding affinities to the PSMA binding sites. They comprise a radioactive isotope or a chelating moiety that can be labeled with a radi...
|
|
WO/2020/219928A1 |
Compositions and methods for transient immunodepletion of specific subsets of a subject's immune cells are disclosed. The methods generally include administering to the subject an effective amount of a radiolabeled antibody against CD19,...
|
|
WO/2020/219615A1 |
Provided herein are phosphodiesterase 4D (PDE4D) inhibitors of Formula (I), including methods of using the same. Also provided are methods of treating subjects suffering from conditions associated with aberrant PDE activity, in particula...
|
|
WO/2020/216334A1 |
Disclosed is a method for preparing a BPA lyophilized preparation, comprising a solution formulating process and a freeze drying process; wherein the solution formulating process comprises: (1) dissolving BPA and a polyol in an aqueous s...
|
|
WO/2020/219475A1 |
Compositions and methods for treating Dry Eye in a human or nonhuman animal subject wherein an effective amount of a pharmaceutical composition comprising an anti-integrin peptide is administered to an eye of the subject. The anti-integr...
|
|
WO/2020/214767A2 |
The present disclosure provides radiolabeled compounds of the formula: (I) and (II), as well as precursor compounds of the formula: (VII) wherein the variables are defined herein. The present disclosure also provides radiopharmaceutical ...
|
|
WO/2020/210919A1 |
This application relates to compounds of Formula (I): [targeting peptide]-N(R1)-X1(R2)L1-[linker]-RX n1 (I). The targeting peptide is cyclo[L-Phe-L-Tyr-L-Lys(iPr)-D-Arg-L-2-Nal-Gly-D-Glu]-L-Lys(
iPr). R1 is H or methyl. X1 is an optional...
|
|
WO/2020/210909A1 |
This application relates to compounds of Formula I. R1a, R1b and R1c is –CO2H, –SO2H, –SO3H, –SO4H, –PO2H, –PO3H or –PO4H. R2 is a linker, e.g. butylene. R3 is a linkage, e.g.–O–, –S–, -S(O)-, S(O)2-, –NHC(O)–, ...
|
|
WO/2020/210914A1 |
The invention relates to compounds for use in imaging and/or for the diagnosis of conditions or diseases associated with an altered level of Neprilysin (NEP/CD10) in a subject having, or suspected of having said conditions or diseases. I...
|
|
WO/2020/202726A1 |
The present invention solves the problem of providing a technique allowing a novel radiolabeled compound to be produced. The present invention is a radio-labeled compound production method comprising: a step of irradiating a radiation be...
|
|
WO/2020/204279A1 |
The present invention provides a composition for diagnosis of fungal infections, the composition comprising 2-deoxy-2-[18F]fluorosorbitol([18F]FDS) as an active ingredient able to allow the rapid and effective diagnosis of fungal infecti...
|
|
WO/2020/202831A1 |
Provided are a method for producing a radiopharmaceutical and a radiopharmaceutical, that during production and after production can preserve a radioactive compound which retains its chemical structure and radioactivity, and that can mai...
|
|
WO/2020/204151A1 |
The present invention provides an aptamer binding to FGF9, which contains a nucleotide sequence represented by formula (I): CAAGGHTGCCG (SEQ ID NO: 37) (I) (wherein H represents A, C or T), etc.
|
|
WO/2020/200283A1 |
In an embodiment of the present invention, a fluorenone ligand compound for an α7 nicotinic acetylcholine receptor represented by the following formula (I) is provided, wherein, X is a 6- to 10-membered nitrogen-containing heterocyclic ...
|
|
WO/2020/197397A1 |
The invention relates to a system for use as a medicament for cancers selected from esophagus, pharynx and larynx, lung, brain, and intestines, comprising a targeting molecule for binding necrotic cells, a chelator, and a radionuclide, t...
|
|
WO/2020/198383A1 |
The disclosure relates to methods of using obeticholic acid for the treatment of various diseases and conditions. In certain instances, the disease or condition is chronic liver disease, nonalcoholic fatty liver disease (NAFLD), nonalcoh...
|
|
WO/2020/198711A1 |
The present invention relates to bifunctional Proteolysis Targeting Chimeric ligands (Protac compounds) comprising a ligase modulator/binder and a molecule that binds to a protein target of interest, and methods of treating various disea...
|
|
WO/2020/055916A9 |
There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a dithiolsaccharide mucolytic a...
|
|
WO/2020/198622A1 |
Disclosed are methods and compositions for repolarizing a tumor associated macrophage (TAM) from M2 to Ml comprising administering to a subject in need thereof an effective dose of a compound comprising a dextran backbone and one or more...
|
|
WO/2020/195504A1 |
A peptide that has an amino acid sequence represented by general formula (I) and collects in cancer-related fibroblasts. (In general formula (I), X11 represents a peptide residue having the following amino acid sequence (a) or (b). (a) A...
|
